Octopus Titan VCT welcomes Julie Nahid Rahman to its Board as Independent Director

– UK, London – Octopus Titan VCT plc (LON: OTV2) today announced the appointment of Julie Nahid Rahman to its Board as an Independent Non-Executive Director effective from 1st August 2023.

“We are delighted to welcome Julie and know she will make a great contribution to the Board. We look forward to benefitting from her wealth of experience in the sector,” said Board Chair, Tom Leader.

Julie Nahid Rahman will also join the Audit Committee, Management Engagement Committee, and Nomination & Remuneration Committee.

About Julie Nahid Rahman

Julie Nahid Rahman is an external advisor to McKinsey’s life sciences practice in addition to her independent consulting. She brings over 20 years of experience across a diverse mix of industries from top-tier global firms including private equity, executive search, and strategy consulting.

She was previously a member of the European healthcare practice at Spencer Stuart leading senior executive and board appointments for life sciences companies and healthcare funds. Before the executive search, she spent a decade as an investor at Visium Healthcare Partners and Paul Capital Healthcare providing creative growth capital to life sciences companies.

Julie began her career as a strategy consultant with Bain & Company advising healthcare and private equity clients.

Julie Nahid Rahman holds an M.B.A. from Harvard Business School and graduated from the Massachusetts Institute of Technology with her M.Sc. in materials science (MIT Langer Lab) and her B.Sc. in chemical engineering.

Source: https://octopusinvestments.com/our-products/venture-capital-trusts/octopus-titan-vct/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.